Have you seen his week's episode of #TheMedicalSisterhood? Mona Shahriari, MD, FAAD, of @YaleMed, spoke on the podcast with her real-life sister and fellow dermatologist, Neda Shahriari, MD, of @BrighamWomens. 🌟 🔗 View: https://t.co/igoAdkH9Tu

A new study suggests #omalizumab may help patients safely continue honeybee venom immunotherapy after severe allergic reactions.🐝 🔗Read more: https://t.co/4bNcFmrOgq #Allergy #Immunology #VenomImmunotherapy

At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF. Watch now: https://t.co/Cp1qmHu51n

Findings from a quality improvement study suggest implementation of empirical donor exclusion and an optimized multi-dose capsule FMT dosing regimen may improve clinical outcomes for patients with Clostridioides difficile infection. Read more: https://t.co/OWrRXlmfS4

There is a new #SkinofColorSavvy podcast in which dermatologists @CrystalAguhMD of @HopkinsMedicine and Loren Krueger, MD, of @EmoryMedicine explore the biological, cultural, and clinical considerations behind curly/coily hair patterns.🎙️ 🔗View: https://t.co/MUaft1MknQ

New post-hoc analysis highlights promise for esmethadone as an adjunctive treatment in patients with antidepressant tolerance (tachyphylaxis). https://t.co/C3Qtt5XJhz #Depression #Psychiatry #MDD

ICYMI: A 5-year follow-up found 76% of children safely reused antibiotics after allergy delabeling without significant reactions. Read more: https://t.co/hE7GuE1FPU #Pediatrics #Allergy

The #FDA has approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of #HidradenitisSuppurativa (HS) in adolescents ≥ 12 years of age and uveitis (UV) in pediatric patients ≥ 2 years of age. View: https://t.co/AiyQSJ8SJp

We spoke with Subhash Banerjee, MD, about AngioSafe's recent announcement of FDA approval for the Santreva-ATK, the first wire-free revascularization catheter for patients with peripheral artery disease. Watch now: https://t.co/DmOxVgOVSk

Clinicians emphasize early patient identification, biomarker integration, and overcoming logistical barriers to optimize biologic therapy use in #asthma and #COPD. Check out the latest conversations happening now:

Positive final results from the phase 3 APPLAUSE-IgAN study of iptacopan (Fabhalta) in adults with IgAN highlight its superiority to placebo in slowing IgAN progression and will support regulatory submissions in 2026. Learn more: https://t.co/hipkaBROnX

🚨Have you seen today's episode of #TheMedicalSisterhood? Host Mona Shahriari, MD, FAAD, of @YaleMed, spoke on the podcast with her real-life sister and fellow dermatologist, Neda Shahriari, MD, of @BrighamWomens. 🌟 🔗 View: https://t.co/igoAdkH9Tu

🚨NEW🚨 In a new #SkinofColorSavvy podcast, dermatologists @CrystalAguhMD of @HopkinsMedicine and Loren Krueger, MD, of @EmoryMedicine explored the biological, cultural, and clinical considerations behind curly/coily hair patterns.🎙️ 🔗View: https://t.co/MUaft1MknQ

A 5-year follow-up found 76% of children safely reused antibiotics after allergy delabeling without significant reactions. Read more: https://t.co/hE7GuE180m #Pediatrics #Allergy

Last month on September 29th, the FDA approved guselkumab (Tremfya), an IL-23 inhibitor, for children aged 6 years or older with #PlaquePsoriasis or #PsA. Check out our interview with Vimal H. Prajapati, MD, @University of Calgary, on this FDA approval:

New hope for patients with HFmrEF/HFpEF. Doctors @MVaduganathan, @SJGreene_md, and @AndrewJSauer unpack finerenone’s FDA approval, FINEARTS-HF findings, and evolving combo therapy strategies in heart failure care. Watch Now: https://t.co/xYLcewaXNG

🚨A new episode of #TheMedicalSisterhood is out now! Host Mona Shahriari, MD, FAAD, of @YaleMed, spoke on the podcast with her real-life sister and fellow dermatologist, Neda Shahriari, MD, of @BrighamWomens. 🌟 🔗 View: https://t.co/LsnxlvJ9eE

Sonelokimab achieved significant ACR50 response at week 12, outperforming placebo in a phase 2 trial for psoriatic #arthritis. Learn more:

ICYMI: The #FDA has approved an sNDA that updates the indication statement for #upadacitinib (RINVOQ) for the treatment of adults with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease. Learn more: https://t.co/2W36PSWJSu

We spoke with Stephen Little, MD, a cardiologist with Houston Methodist Health, to discuss the merits of TTVR versus T-TEER in treating tricuspid regurgitation - and how clinicians can help implement these new therapies. Watch now: https://t.co/akky5DxiFC